Comparison of the Effectiveness of ABSI and its Z-Score in Predicting the Prevalence of Dyslipidemia

Authors

DOI:

https://doi.org/10.69547/tsfjb.v1i1.12

Keywords:

Z-score of ABSI, Dyslipidemia, Lipoproteins, CHD, LBSIZ

Abstract

Dyslipidemia is an abnormality of any lipoprotein fractions (TC, TG, LDL, and HDL). It is important to study the population to monitor risk factors for dyslipidemia and coronary heart disease (CHD). However, few population-based studies related to lipid levels were conducted in Pakistan. In this cross-sectional study, the prevalence of dyslipidemia in the local population (80 participants; 30 females and 50 males) was assessed. The studied population showed abnormalities in at least one lipid fraction including TC, LDL, TG, and HDL. According to abnormal lipid fractions, 89% of the participants were dyslipidemic with more prevalence in the rural population. The gender-wise comparison showed that males were more likely to have dyslipidemia than females due to their abnormal lipid profile. The most common form of dyslipidemia was low HDL (77%), followed by high TG (36%). Various traditionally introduced anthropometric and metabolic parameters were assessed to determine the severity of dyslipidemia, but they were not strong predictors of dyslipidemia due to their limitations. To overcome these limitations, newly introduced anthropometric parameters, namely LBSIZ and the Z-score of ABSI were applied. However, ABSI and its Z-score were also not strong predictors of dyslipidemia.

References

Shi J, Yang Y, Cheng A, Xu G, He F. Metabolism of vascular smooth muscle cells in vascular diseases. Am J Physiol Heart Circ Physiol. 2020 Sep;319(3):H613-631. https://doi.org/10.1152/AJPHEART.00220.2020.

Mannucci PM, Harari S, Franchini M. Novel evidence for a greater burden of ambient air pollution on cardiovascular disease. Haematologica. 2019;104(12):2349. https://doi.org/10.3324/haematol.2019.219816.

Xing L, et al. Epidemiology of dyslipidemia and associated cardiovascular risk factors in northeast China: A cross-sectional study. Nutr Metab Cardiovasc Dis. 2020 Nov;30(12):2262-2270. https://doi.org/10.1016/J.NUMECD.2020.07.032.

Hedayatnia M, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis. 2020 Mar;19(1):1-11. https://doi.org/10.1186/S12944-020-01204-Y.

Muhimpundu MA, et al. Road map for leadership and management in public health: a case study on noncommunicable diseases program managers’ training in Rwanda. Int J Health Promot Educ. 2018 Dec;57(2):82-97. https://doi.org/10.1080/14635240.2018.1552178.

Fogacci F, Borghi C, Cicero AFG. New evidences on the association between high-density lipoprotein cholesterol and cardiovascular risk: a never ending research story. Eur J Prev Cardiol. 2022 Mar;29(5):842-843. https://doi.org/10.1093/eurjpc/zwac015.

Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): An underrecognized genetic risk factor for malignant coronary artery disease in young Indians. Indian Heart J. 2019;71(3):184-198. https://doi.org/10.1016/j.ihj.2019.04.007.

Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC Public Health. 2021;21(1):401. https://doi.org/10.1186/s12889-021-10429-0

Zuccala E, Horton R. Reframing the NCD agenda: a matter of justice and equity. Lancet. 2020;396(10256):939-940. https://doi.org/10.1016/S0140-6736(20)31910-3

Zimmermann MB. The remarkable impact of iodisation programmes on global public health. Proc Nutr Soc. 2023;82(2):113-119. https://doi.org/10.1017/S0029665122002762

Gaidai O, Cao Y, Loginov S. Global cardiovascular diseases death rate prediction. Curr Probl Cardiol. 2023. https://doi.org/10.1016/j.cpcardiol.2023.101622.

Sukumar S, Brodsky M, Hussain S, et al. Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission. Blood Adv. 2022;6(4):1264-1270. https://doi.org/10.1182/bloodadvances.202000416

Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022;43(4):611-653. https://doi.org/10.1210/endrev/bnab037

Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, Bechara MD, Sloan KP, Sloan LA. Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes Metab Res Rev. 2022;38(3):e3502. https://doi.org/10.1002/dmrr.3502

Kizilaslan N. The Impact of The nutrition situations and physical activities of academicians on anthropometric measurements and blood parameters. Authorea Prepr. 2021.

Koyama, S., Ito, K., Terao, C., Akiyama, M., Horikoshi, M., Momozawa, Y., Matsunaga, H., Ieki, H., Ozaki, K., Onouchi, Y., Takahashi, A., Nomura, S., Morita, H., Akazawa, H., Kim, C., Seo, J. S., Higasa, K., Iwasaki, M., Yamaji, T., Komuro, I. Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. Nature genetics. (2020);52(11), 1169-1177. https://doi.org/10.1038/s41588-020-0705-3

Zaid M, Hasnain S. Plasma lipid abnormalities in Pakistani population: trends, associated factors, and clinical implications. Braz J Med Biol Res. 2018 Jul;51(9):e7239. https://doi.org/10.1590/1414-431X20187239.

Feingold KR, Grunfeld C. Introduction to Lipids and Lipoproteins. Endotext. Jan. 2021. Accessed: Nov. 05, 2023. [Online]. Available: https://www.ncbi. nlm.nih.gov/books/NBK305896/

Stuchell-Brereton MD, et al. Apolipoprotein E4 has extensive conformational heterogeneity in lipid-free and lipid-bound forms. Proc Natl Acad Sci. 2023;120(7):e2215371120. https://doi.org/10.1073/pnas.2215371120

Chan DC, Watts GF. Apolipoproteins as markers and managers of coronary risk. QJM. 2006 May;99(5):277-287. https://doi.org/10.1093/qjmed/hcl027.

Wengrofsky P, Lee J, Makaryus AN. Dyslipidemia and Its Role in the Pathogenesis of Atherosclerotic Cardiovascular Disease: Implications for Evaluation and Targets for Treatment of Dyslipidemia Based on Recent Guidelines. Dyslipidemia. Apr. 2019. https://doi.org/10.5772/INTECHOPEN.85772.

Oliveira JS, Pinheiro MB, Fairhall N, et al. Evidence on Physical Activity and the Prevention of Frailty and Sarcopenia Among Older People: A Systematic Review to Inform the World Health Organization Physical Activity Guidelines. J Phys Act Health. 2020;17(12):1247-1258. Published 2020 Aug 11. https://doi.org/10.1123/ jpah.2020-0323

Naz L, Umair M. Role of Gender Disaggregate Statistics in Urban Planning and Development in Pakistan. Promot Stat Pract Collab Dev Ctries. 2022. https://doi.org/9781003261148

Sorjonen, K., Nilsonne, G., Falkstedt, D., Hemmingsson, T., Melin, B., & Ingre, M. (2020). A comparison of models with weight, height, and BMI as predictors of mortality. Obesity science & practice, 7(2), 168–175. https://doi.org/10.1002/osp4.473

Williams H, Mack CD, Li SCH, Fletcher JP, Medbury HJ. Nature versus Number: Monocytes in Cardiovascular Disease. International Journal of Molecular Sciences. 2021; 22(17):9119. https://doi.org/10.3390/ijms22179119

Naureen I. Study the Association of C-Reactive Protein and Risk of Cardiovascular Disease in Heart Patients above the Age of 50 Years. Saudi J Biomed Res. 2021;6(10):233-240. https://doi.org/10.36348/sjbr.2021 .v06i10.001

Lee, J. W., Lim, H., Kim, J. H., & Kim, H. S. (2021). Reassessment of Inclusion Criteria in the 2013 the American College of Cardiology and the American Heart Association Cholesterol Guidelines for Cardiovascular Disease Prevention. Journal of clinical neurology (Seoul, Korea), 17(1), 86–95. https://doi.org/10.3988/jcn.2021.17.1.86

Mohanraj S, Velmurugan G, Swaminathan K, Ramakrishnan A. Prevalence and risk factors for dyslipidemia among South Indian adults: A community-based NCD study. Int J Diabetes Dev Ctries. 2023:1-10. https://doi.org/10.1007/s13410-023-01202-7

Zapata, J.K., Azcona-Sanjulian, M.C., Catalán, V. et al. BMI-based obesity classification misses children and adolescents with raised cardiometabolic risk due to increased adiposity. Cardiovasc Diabetol 22, 240 (2023). https://doi.org/10.1186/s12933-023-01972-8

Jorge-Galarza E, Medina-Urrutia A, Reyes-Barrera J, Torres-Tamayo M, Montaño-Estrada LF, Páez-Arenas A, Massó-Rojas F, Juárez-Rojas JG. Adipose tissue dysfunction serum markers are associated with high-density lipoprotein size and glycation in the early stages of type 2 diabetes. Lipids Health Dis. 2023;22(1):89. https://doi.org/10.1186/s12944-023-01847-7

Opoku, S., Gan, Y., Fu, W. et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). BMC Public Health 19, 1500 (2019). https://doi.org/10.1186/s12889-019-7827-5

Ding, M., Wennberg, A., Gigante, B., Walldius, G., Hammar, N., & Modig, K. (2022). Lipid levels in midlife and risk of atrial fibrillation over 3 decades-Experience from the Swedish AMORIS cohort: A cohort study. PLoS medicine, 19(8), e1004044. https://doi.org/10. 1371/journal.pmed.1004044.

Carbone, S., Canada, J. M., Billingsley, H. E., Siddiqui, M. S., Elagizi, A., & Lavie, C. J. (2019). Obesity paradox in cardiovascular disease: where do we stand?. Vascular health and risk management, 15, 89–100. https://doi.org/10.2147/VHRM.S168946

Chung H. S. (2023). FRI052 Z-score Of The Log-transformed A Body Shape Index As A Screening Tool For Sarcopenia In Population With Central Obesity. Journal of the Endocrine Society, 7(Suppl 1), bvad114.063. https://doi.org/10.1210/jendso/bvad114.063

Chung H. S. (2023). FRI052 Z-score Of The Log-transformed A Body Shape Index As A Screening Tool For Sarcopenia In Population With Central Obesity. Journal of the Endocrine Society, 7(Suppl 1), bvad114.063. https://doi.org/10.1210/jendso/bvad114.063

Downloads

Published

2023-06-15

How to Cite

Shoaib , M., & Khan, M. S. (2023). Comparison of the Effectiveness of ABSI and its Z-Score in Predicting the Prevalence of Dyslipidemia. TSF Journal of Biology , 1(1), 51–66. https://doi.org/10.69547/tsfjb.v1i1.12